Loading cancer entity…
Loading cancer entity…
Clinical trials
8,119 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,289)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00187161 | Treatment of Burkitt Lymphoma/Leukemia and B Large Cell NHL | completed | Phase 2 | 68 | St. Jude Children's Research HospitalOTHER | 1 | Jun 4, 2008 | clinicaltrials |
| NCT00177554 | Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma | completed | Phase 2 | 60 | University of PittsburghOTHER | 1 | May 29, 2008 | clinicaltrials |
| NCT00455416 |
| Dietary Intervention in Follicular Lymphoma(KLYMF) |
| unknown |
| Phase 2 |
| 45 |
| Oslo University HospitalOTHER |
| 1 |
| May 21, 2008 |
| clinicaltrials |
| NCT00320476 | VTD Followed By MPT Maintenance As a First Line Treatment For The Patients With MM Who Are Non-Transplant Candidates | completed | Phase 2 | 35 | Korean Multiple Myeloma Working PartyOTHER | 1 | May 6, 2008 | clinicaltrials |
| NCT00349115 | TCD Followed by autoSCT for Newly Diagnosed MM Patients | unknown | Phase 2 | 43 | Korean Multiple Myeloma Working PartyOTHER | 1 | May 6, 2008 | clinicaltrials |
| NCT00250861 | Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's Lymphoma | terminated | Phase 2 | 110 | US Oncology ResearchINDUSTRY | 1 | Apr 21, 2008 | clinicaltrials |
| NCT00510471 | Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma | terminated | Phase 2 | — | Genitope CorporationINDUSTRY | 1 | Mar 18, 2008 | clinicaltrials |
| NCT00001237 | Pilot Protocol for the Treatment of Patients With Small Non-Cleaved and Diffuse Large Cell Lymphomas | completed | Phase 2 | 120 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001430 | A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas | completed | Phase 2 | 49 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001567 | A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia | completed | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001750 | Comparing Treatments for Multiple Myeloma | completed | Phase 2 | 32 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00066092 | Pegfilgrastim PBPC Mobilization Study | completed | Phase 2 | 41 | AmgenINDUSTRY | 0 | Feb 28, 2008 | clinicaltrials |
| NCT00063713 | VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma | completed | Phase 2 | 152 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 11, 2008 | clinicaltrials |
| NCT00085696 | VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma | completed | Phase 2 | 66 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 11, 2008 | clinicaltrials |
| NCT00304720 | Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor | unknown | Phase 2 | 40 | Colorado Blood Cancer InstituteOTHER | 1 | Feb 8, 2008 | clinicaltrials |
| NCT00090090 | Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 2 | 114 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Jan 15, 2008 | clinicaltrials |
| NCT00141700 | Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma | terminated | Phase 2 | 30 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 10, 2008 | clinicaltrials |
| NCT00044902 | Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade) | completed | Phase 2 | — | AmgenINDUSTRY | 0 | Dec 28, 2007 | clinicaltrials |
| NCT00116441 | Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma | completed | Phase 1 / Phase 2 | 22 | Cell GenesysINDUSTRY | 1 | Dec 24, 2007 | clinicaltrials |
| NCT00086216 | Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 30 | Callisto PharmaceuticalsINDUSTRY | 1 | Dec 21, 2007 | clinicaltrials |
| NCT00165347 | Protein Tyrosine Kinases (PTK) in Multiple Myeloma | completed | Phase 2 | 10 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 21, 2007 | clinicaltrials |
| NCT00367497 | Safety and Efficacy Study of Salvage Chemotherapy (R-ESHAP) to Treat Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma | terminated | Phase 2 | 5 | Keio UniversityOTHER | 1 | Nov 20, 2007 | clinicaltrials |
| NCT00120198 | Pegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymphoma Patients | terminated | Phase 2 | 50 | Geriatric Oncology ConsortiumOTHER | 1 | Nov 16, 2007 | clinicaltrials |
| NCT00558220 | R-MegaCHOP-ESHAP-BEAM in Patients With High-Risk Aggressive B-Cell Lymphomas(R-MCEB) | completed | Phase 2 | 106 | Czech Lymphoma Study GroupOTHER | 1 | Nov 14, 2007 | clinicaltrials |
| NCT00556127 | Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma(DLBCL) | completed | Phase 2 | 94 | Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle LeucemieOTHER | 1 | Nov 9, 2007 | clinicaltrials |
| NCT00057447 | Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients | terminated | Phase 1 / Phase 2 | 24 | InterMuneINDUSTRY | 1 | Nov 1, 2007 | clinicaltrials |
| NCT00062894 | Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab | completed | Phase 1 / Phase 2 | 12 | GlaxoSmithKlineINDUSTRY | 1 | Sep 17, 2007 | clinicaltrials |
| NCT00061672 | Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma | completed | Phase 2 | 67 | AbbottINDUSTRY | 1 | Aug 15, 2007 | clinicaltrials |
| NCT00491127 | Cisplatin With Gemcitabine With Dexamethasone in Patients With Aggressive Non-Hodgkin's Lymphoma | completed | Phase 2 | 10 | Eli Lilly and CompanyINDUSTRY | 1 | Jun 25, 2007 | clinicaltrials |
| NCT00086034 | Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma | completed | Phase 2 | 35 | Pharmacyclics LLC.INDUSTRY | 1 | May 15, 2007 | clinicaltrials |
| NCT00109356 | Study of AQ4N in Patients With Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Leukemia | unknown | Phase 1 / Phase 2 | 55 | NovaceaINDUSTRY | 1 | May 7, 2007 | clinicaltrials |
| NCT00143884 | Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood | terminated | Phase 2 | 30 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 23, 2007 | clinicaltrials |
| NCT00089596 | Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers | completed | Phase 1 / Phase 2 | 10 | ViaCellINDUSTRY | 1 | Apr 12, 2007 | clinicaltrials |
| NCT00455286 | a Phase II Study in Primary Central Nervous System Lymphoma | unknown | Phase 2 | 25 | National Health Research Institutes, TaiwanOTHER | 1 | Apr 4, 2007 | clinicaltrials |
| NCT00157274 | Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome | unknown | Phase 2 | 20 | Latin American Cooperative Onco-Haematology Group - PeruOTHER | 1 | Apr 3, 2007 | clinicaltrials |
| NCT00438581 | Study Combining Zevalin With High-Dose Chemotherapy Prior to Autologous StemCell Transplant in Patients With Relapsed, Refractory, or Transformed Non-Hodgkin's Lymphoma(Zevalin) | unknown | Phase 2 | 40 | McGill UniversityOTHER | 1 | Feb 27, 2007 | clinicaltrials |
| NCT00327314 | Non-Myeloablative Allogeneic Transplantation From Unrelated Donors in Multiple Myeloma | unknown | Phase 2 | 100 | Azienda Ospedaliera San Giovanni BattistaOTHER | 1 | Dec 28, 2006 | clinicaltrials |
| NCT00399867 | Simvastatin as Inhibitor of Cell Adhesion Mediated Drug Resistance in Patients With Refractory Multiple Myeloma. | completed | Phase 2 | 30 | Ludwig-Maximilians - University of MunichOTHER | 0 | Dec 20, 2006 | clinicaltrials |
| NCT00358020 | Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients | completed | Phase 2 | 30 | University of Turin, ItalyOTHER | 1 | Dec 4, 2006 | clinicaltrials |
| NCT00396045 | Melphalan, Prednisone, and CC-5013 (Revlimid) as Induction Therapy in Multiple Myeloma | completed | Phase 1 / Phase 2 | 54 | University of Turin, ItalyOTHER | 1 | Nov 30, 2006 | clinicaltrials |
| NCT00048464 | T Cell Immunotherapy for Multiple Myeloma Patients Undergoing a Bone Marrow Transplant | unknown | Phase 1 / Phase 2 | 35 | Xcyte TherapiesINDUSTRY | 1 | Nov 7, 2006 | clinicaltrials |
| NCT00393107 | Safety and Efficacy of Fludarabine and Cyclophosphamide + Rituximab | completed | Phase 2 | 54 | Gruppo Italiano Studio LinfomiOTHER | 1 | Oct 26, 2006 | clinicaltrials |
| NCT00261612 | Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma | unknown | Phase 2 | 16 | Medical University of ViennaOTHER | 1 | Oct 18, 2006 | clinicaltrials |
| NCT00300664 | A Randomized Trial of Human Growth Hormone (hGH) vs Placebo in Intensively Treated Haemato-Oncology Patients. | completed | Phase 2 / Phase 3 | 150 | Royal Marsden NHS Foundation TrustOTHER | 0 | Oct 13, 2006 | clinicaltrials |
| NCT00384553 | Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-Lymphoma | unknown | Phase 1 / Phase 2 | 30 | University of MagdeburgOTHER | 1 | Oct 6, 2006 | clinicaltrials |
| NCT00382694 | Fludarabine Added to Induction Treatment in Untreated Multiple Myeloma Patients | unknown | Phase 2 | 80 | Nordic Myeloma Study GroupOTHER | 1 | Sep 29, 2006 | clinicaltrials |
| NCT00333008 | A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status. | unknown | Phase 2 | 27 | The Alvin and Lois Lapidus Cancer InstituteOTHER | 1 | Sep 26, 2006 | clinicaltrials |
| NCT00378755 | Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMM | unknown | Phase 2 | 62 | Korean Multiple Myeloma Working PartyOTHER | 1 | Sep 22, 2006 | clinicaltrials |
| NCT00180895 | Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL | terminated | Phase 2 | 40 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 11, 2006 | clinicaltrials |
Data updated 23 days agoSource updated Jun 4, 2008source: clinicaltrials